BBL
OVID icon

Beck Bode LLC’s Ovid Therapeutics OVID Stock Holding History

Beck Bode LLC’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-350
Closed -$1K – 234
2021
Q2 		$1K Buy
+350
New +$1.38K ﹤0.01% 310
2020
Q4 		– Sell
-350
Closed -$2K – 193
2020
Q3 		$2K Buy
+350
New +$2.34K ﹤0.01% 288

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $783M AUM 81.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Beck Bode LLC's OVID Position: Q3 2021 in Review

Beck Bode LLC sold out of Ovid Therapeutics (OVID) in Q3 2021, closing a stake of 350 shares — an estimated $1K sold.

Beck Bode LLC first reported a position in OVID in Q3 2020 and held it in 2 quarters. The position peaked at $2K in Q3 2020. 72 funds tracked by Wall St. Rank hold OVID as of Q3 2021.

  • Beck Bode LLC reported no remaining Ovid Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Beck Bode LLC sold 350 Ovid Therapeutics shares in Q3 2021, an estimated $1K.
  • Beck Bode LLC first reported a position in Ovid Therapeutics in Q3 2020 and held it in 2 quarters.
  • Beck Bode LLC's Ovid Therapeutics position peaked at $2K in Q3 2020.
  • 72 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2021.

Based on Beck Bode LLC's 13F filing for Q3 2021, filed 22 Oct 2021.